Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer

BackgroundThe full extent of chromosomal alterations and their biological implications in early breast carcinogenesis has not been well examined. In this study, we aimed to identify chromosomal alterations associated with poor prognosis in early-stage breast cancers (EBC).MethodsA total of 145 EBCs (stage I and II) were examined in this study. We analyzed copy number alterations in a discovery set of 48 EBCs using oligoarray-comparative genomic hybridization. In addition, the recurrently altered regions (RARs) associated with poor prognosis were validated using an independent set of 97 EBCs.ResultsA total of 23 RARs were defined in the discovery set. Six were commonly detected in both stage I and II groups (> 50%), suggesting their connection with early breast tumorigenesis. There were gains on 1q21.2-q21.3, 8q24.13, 8q24.13-21, 8q24.3, and 8q24.3 and a loss on 8p23.1-p22. Among the 23 RARs, copy number gains on 16p11.2 (NUPR1) and 17q12 (ERBB2) showed a significant association with poor survival (P = 0.0186 and P = 0.0186, respectively). The patients simultaneously positive for both gains had a significantly worse prognosis (P = 0.0001). In the independent replication, the patients who were double-positive for NUPR1-ERBB2 gains also had a significantly poorer prognosis on multivariate analysis (HR = 7.31, 95% CI 2.65-20.15, P = 0.0001).ConclusionsThe simultaneous gain of NUPR1 and ERBB2 can be a significant predictor of poor prognosis in EBC. Our study will help to elucidate the molecular mechanisms underlying early-stage breast cancer tumorigenesis. This study also highlights the potential for using combinations of copy number alterations as prognosis predictors for EBC.

[1]  E. Romond,et al.  Clinical updates on EGFR/HER targeted agents in early-stage breast cancer. , 2010, Clinical breast cancer.

[2]  S. Hirohashi,et al.  Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c‐erbB‐2 expression patterns in both the non‐invasive and invasive portions , 1998, Pathology international.

[3]  Suk Woo Nam,et al.  ArrayCyGHt: a web application for analysis and visualization of array-CGH data , 2005, Bioinform..

[4]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[5]  P. Saigo,et al.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Dino Amadori,et al.  The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.

[7]  A. Walch,et al.  Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. , 2008, Human pathology.

[8]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[9]  Mikael Lundin,et al.  Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[11]  O. Fodstad,et al.  Emerging role of nuclear protein 1 (NUPR1) in cancer biology , 2009, Cancer and Metastasis Reviews.

[12]  M. Ringnér,et al.  Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.

[13]  Jiawei Han,et al.  CPAR: Classification based on Predictive Association Rules , 2003, SDM.

[14]  Y. Chung,et al.  The potential role of VPREB1 gene copy number variation in susceptibility to rheumatoid arthritis. , 2011, Molecular immunology.

[15]  C. Livasy,et al.  Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis , 2004, Breast Cancer Research and Treatment.

[16]  A. Krasnitz,et al.  Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients , 2010, Science Translational Medicine.

[17]  B. Thürlimann,et al.  Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Miller,et al.  Why is breast-cancer mortality declining? , 2003, The Lancet. Oncology.

[19]  C. Morrison,et al.  Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis , 2010, Modern Pathology.

[20]  E. Hovig,et al.  Expression of a novel factor in human breast cancer cells with metastatic potential. , 1999, Cancer research.

[21]  J. Iovanna,et al.  Nupr1: The Swiss‐knife of cancer , 2011, Journal of cellular physiology.

[22]  J. Gray,et al.  The genetics and genomics of cancer , 2003, Nature Genetics.

[23]  Tae-Min Kim,et al.  Copy number variations in East-Asian population and their evolutionary and functional implications , 2009, Human molecular genetics.

[24]  Y. Chung,et al.  Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array , 2009, Experimental & Molecular Medicine.

[25]  P. Nederlof,et al.  Array-CGH and breast cancer , 2006, Breast Cancer Research.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[28]  W. Lane,et al.  Predicting recurrence in axillary-node negative breast cancer patients , 2004, Breast Cancer Research and Treatment.

[29]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[30]  V. Beral,et al.  Sudden fall in breast cancer death rates in England and Wales , 1995, The Lancet.

[31]  S. Singletary,et al.  Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years , 2002, Annals of surgery.

[32]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[33]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Ashworth,et al.  An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.

[35]  Wonshik Han,et al.  Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer , 2008, International journal of cancer.

[36]  J. Pollack,et al.  Genomic instability in breast cancer: Pathogenesis and clinical implications , 2010, Molecular oncology.

[37]  Tomasz Imielinski,et al.  Database Mining: A Performance Perspective , 1993, IEEE Trans. Knowl. Data Eng..

[38]  Mary E. Edgerton,et al.  Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer , 2011, PloS one.

[39]  H. Tsuda.  Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression , 2009, Breast cancer.

[40]  H. Jeon,et al.  Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer , 2008, Journal of Korean medical science.